disclosed that in lung cancer, ERO1L promotes IL6R secretion to activate the NF-κB pathway, leading to an upregulation of MUC16 gene expression, and the C-terminal of MUC16 further fosters the EMT phenotype and IL6 release, creating a positive feedback loop that exacerbates lung cancer progression (57). Here, ERO1A is linked to lung carcinoma.